Cyclopharm Limited (AU:CYC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cyclopharm Limited has secured its first purchase orders from two US Veterans Health Administration hospitals for its Technegas System, marking a significant step in its expansion within the United States. These orders, set for a five-year term, will enable the installation of Technegas, a cutting-edge diagnostic tool for lung diseases, in early 2025, potentially enhancing care for veterans. This development could serve as a model for further agreements with other VA hospitals, promising immediate revenue generation for Cyclopharm.
For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.